Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Qiagen NV
The company has developed a technology that uses engineered DNA to reprogram cancer cells, forcing them to produce substances that could be used to help image, detect or even destroy them.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations first day of the meeting.
Keeping Track: US FDA Oncology Approvals For Ferring’s Gene Therapy Adstiladrin And Mirati’s Targeted Therapy Krazati
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Krazati was approved for second-line NSCLC with labeling that positions it ahead of Lumakras on efficacy, but not safety. Pricing is slightly higher than for Amgen’s drug.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Other Names / Subsidiaries
- Amnisure International LLC
- Biobase, Biotage
- Corbett Life Science Pty. Ltd.
- Digene Corporation
- eGene, Inc.
- ESE GmbH
- Ingenuity Systems Inc
- Genaco Biomedical Products, Inc.
- MO BIO Laboratories
- NeuMoDx Molecular, Inc.
- OmicSoft Corporation
- SABiosciences Corporation
- Ipsogen S.A.
- Qiagen Manchester Limited
- Qiagen N.V.
- Xeragon Inc.
- QIAGEN (Suzhou) Translational Medicine Co., Ltd.
- MEDx Translational Medicine
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.